Business Wire

ADVA and PSNC showcase 1200G channel transmission at SC19

19.11.2019 17:45:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that it’s hosting a joint showcase with PSNC at SC19 that features the industry’s first 1200Gbit/s optical channel transmission. Built upon the ADVA FSP 3000 TeraFlex™ terminal, the demo underscores the power of adaptive technology to maximize bandwidth efficiency in any network scenario. Using fractional QAM capabilities to boost fiber utilization and channel capacity, the demo highlights how network operators and enterprises can cost-effectively inject capacity into their networks without major upgrades. At SC19, TeraFlex™ will carry 1200Gbit/s channels in a 150GHz window or 800Gbit/s channels in a 100GHz window, delivering an industry-leading spectral efficiency of 8bit/s/Hz. These figures set a new benchmark for a commercially available product. The ADVA FSP 3000 TeraFlex™ has now been shipping for several months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005670/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)

“As we approach the Shannon Limit, our compact and open FSP 3000 TeraFlex™ provides an entirely new route to network capacity expansion. This demo reveals how operators can enhance optical paths and reduce cost per bit right now,” said Christoph Glingener, CTO, ADVA. “Transmission terminal design is all about utilizing fiber in the most efficient way, and that’s why our FSP 3000 TeraFlex™ is the high-speed terminal of choice. By providing a 1200Gbit/s channel that consumes only 150GHz of spectrum, we’re leading the industry with spectral efficiency and channel capacity. Compared with the promise of rival 800Gbit/s solutions that are still many months away, we’re delivering 50% more capacity today – and with the added bonus of significantly better reach.”

Presented at SC19, the live demo highlights how spectral efficiency is key to maximizing bandwidth in existing networks. It shows how super-channels in increments of 50GHz are ideal for maximizing client port flexibility while ensuring compatibility with legacy line systems. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, the ADVA FSP 3000 TeraFlex™ can support 1200Gbit/s channels carrying three 400Gbit/s clients or 800Gbit/s channels carrying two 400Gbit/s clients. The reach and spectral efficiency of the dual-core coherent engine implementation is superior to future single-core 800Gbit/s concepts that have reduced client port flexibility and often leave spectrum unutilized.

“Terabit channels are fast becoming essential. Our network enables Europe’s scientific community to share huge data sets and access the most advanced supercomputing applications. But empowering those researchers to stay at the forefront of discovery requires a new level of reach and spectral efficiency. With this demo, we’re showing how mission-critical long-haul networks like ours, which are not fiber-rich, can meet unprecedented data demand,” commented Artur Binczewski, director, Network Division, PSNC. “The ADVA FSP 3000 TeraFlex™ provides the flexibility and granularity needed to squeeze maximum value from our fiber plant. Now we can transmit twelve 100Gbit/s or three 400Gbit/s signals in a single Terabit channel that consumes just 150GHz of spectrum. That level of efficiency enables us to achieve more than we ever thought possible with our DCI network.”

The demo will be on display at SC19 at booth 1955 until Thursday, November 21.

Further details of the demo are available in these slides: https://adva.li/sc19-slides.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About PSNC
Poznan Supercomputing and Networking Center (PSNC) affiliated to the Institute of Bioorganic Chemistry of the Polish Academy of Sciences is an internationally known node of the European Research Area in the field of IT infrastructure of science and an important R&D center in the field of information and communication technologies (ICT). As a development center of e-Infrastructure, PSNC designed and built the Metropolitan Network POZMAN, High Performance Computing Center and the national broadband network PIONIER, maintained and still developed by PSNC. We are an institution of high development potential. A positive consequence of the Centre's exemplary activity in acquiring and implementing projects was the establishment of broad cooperation with international institutions. Projects developed at PSNC include cooperation with 927 units from 59 countries. All projects are focused on IT technology and concern new generation networks, grids, portals, digital libraries, IT energy efficiency, climate, weather, air quality, new sources of energy, digital humanities, personalized medicine, intelligent agriculture, industry 4.0, astronomy, bioinformatics, Big Data analysis, artificial intelligence, New Media, education, Smart City, cyber security. The list of areas of activity in which PSNC undertakes work is constantly expanding, providing an important example of taking up new technological challenges. www.man.poznan.pl/online/en

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye